X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.fdanews.com/articles/208842-obseva-scraps-plans-for-uterine-fibroid-candidate?v=preview
https://www.fiercepharma.com/pharma/ominous-fda-talks-obseva-scraps-lead-womens-health-drug-plots-layoffs-major-restructuring
https://www.globenewswire.com/news-release/2022/06/28/2470795/0/en/ObsEva-Announces-UK-MHRA-Marketing-Authorization-for-Yselty-linzagolix-an-Oral-GnRH-Antagonist-for-the-Treatment-of-Uterine-Fibroids.html
https://www.globenewswire.com/news-release/2022/05/25/2449884/0/en/ObsEva-Presents-Clinical-Data-on-Oral-GnRH-Antagonist-Linzagolix-at-Multiple-Congresses.html
https://www.globenewswire.com/news-release/2022/04/25/2427956/0/en/ObsEva-Announces-Confirmation-of-Positive-CHMP-Opinion-for-Linzagolix-an-Oral-GnRH-Antagonist-for-the-Treatment-of-Uterine-Fibroids.html
https://www.globenewswire.com/news-release/2022/04/25/2427733/0/en/ObsEva-Announces-Confirmation-of-Positive-CHMP-Opinion-for-Linzagolix-an-Oral-GnRH-Antagonist-for-the-Treatment-of-Uterine-Fibroids.html
https://www.globenewswire.com/news-release/2022/03/22/2407239/0/en/ObsEva-Announces-Additional-Efficacy-Results-for-Linzagolix-200-mg-with-Add-Back-Therapy-ABT-and-Linzagolix-75-mg-without-ABT-in-the-Phase-3-EDELWEISS-3-Trial-in-Patients-with-Mode.html
https://www.globenewswire.com/news-release/2022/02/04/2379499/0/en/ObsEva-Provides-Update-on-EU-Marketing-Authorisation-Process-for-Linzagolix-an-Oral-GnRH-Antagonist-for-the-Treatment-of-Uterine-Fibroids.html
https://www.globenewswire.com/news-release/2022/01/06/2362100/0/en/ObsEva-Announces-Positive-Topline-Results-for-Linzagolix-200-mg-with-Add-Back-Therapy-in-the-Phase-3-EDELWEISS-3-Trial-in-Patients-with-Moderate-to-Severe-Endometriosis-Associated-.html
https://www.globenewswire.com/news-release/2021/12/17/2354391/0/en/ObsEva-Announces-Positive-CHMP-Opinion-for-Linzagolix-an-Oral-GnRH-Antagonist-for-the-Treatment-of-Uterine-Fibroids.html
https://www.globenewswire.com/news-release/2021/12/10/2349803/0/en/ObsEva-Hosts-Symposium-and-Presents-Clinical-Data-on-Oral-GnRH-Antagonist-Linzagolix-at-SEUD-Congress-2021.html
https://www.globenewswire.com/news-release/2021/10/20/2316992/0/en/ObsEva-Presents-Clinical-Data-on-Oral-GnRH-Antagonist-Linzagolix-for-the-Treatment-of-Uterine-Fibroids-at-ASRM-2021-Scientific-Congress-Expo.html
https://www.biospace.com/article/releases/obseva-announces-relationship-with-syneos-health-to-commercialize-linzagolix-/?s=71
https://www.empr.com/home/news/drugs-in-the-pipeline/linzagolix-nda-submitted-for-uterine-fibroid-treatment/
https://www.globenewswire.com/news-release/2021/09/15/2297146/0/en/ObsEva-Announces-Submission-of-New-Drug-Application-to-U-S-FDA-for-Linzagolix-for-the-Treatment-of-Uterine-Fibroids.html
https://www.globenewswire.com/news-release/2020/11/24/2132406/0/en/ObsEva-SA-Submits-Marketing-Authorization-Application-to-the-European-Medicines-Agency-for-YSELTY-linzagolix-for-the-Treatment-of-Women-with-Uterine-Fibroids.html
https://www.globenewswire.com/news-release/2019/05/09/1819921/0/en/ObsEva-SA-Announces-Initiation-of-Phase-3-EDELWEISS-2-and-3-Trials-of-Linzagolix-for-Endometriosis-Associated-Pain-in-U-S-Canada-and-Europe.html
Market Place
Share 
